29 September 2021
Kirkland Represents ARYA Sciences Acquisition Corp IV on Acquisition of Amicus Therapeutics’ Gene Therapy Business
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Ryan Brissette Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Jonathan Davis Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Peter Fritz | Kirkland & Ellis | Associate | corporate | Not stated |
| Peter Seligson | Kirkland & Ellis | Partner | capital markets | Not stated |
| Sara Zablotney | Kirkland & Ellis | Partner | tax | Not stated |
| Mark Schwed | Kirkland & Ellis | Partner | tax | Not stated |
| Adam Petravicius | Kirkland & Ellis | Partner | technology & IP transactions | Not stated |
| Shellie Freedman | Kirkland & Ellis | Partner | technology & IP transactions | Not stated |
Stated terms
- Stated value
- USD 200m (approximately $200 million)
- What the figure measures
- Not stated
- Client
- Not stated
- Counterparties
- Amicus Therapeutics (Sell-side)